Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From UCB S.A.
Partners Apotex and Ambio have announced approval of a second US teriparatide generic from the FDA, adding another Forteo rival to the market and removing hopes that Teva’s recently approved first generic could benefit from 180 days of market exclusivity. Further competition is also in the works with Amphastar awaiting FDA action on a further teriparatide ANDA.
Partners Fresenius Kabi and Formycon have submitted a US filing for their FYB202 ustekinumab biosimilar rival to Stelara.
Japan has announced the latest evaluation results under its cost effectiveness assessment scheme. But how does it work and how much have prices been revised so far under the four-year-old program following discussions between pharma firms and authorities?
Embecta, which recently completed its spin-off from Becton Dickinson, is forging ahead with its insulin injector-based business strategy, GLP-1s be damned.
- Research, Analytical Equipment & Supplies
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- Celltech Pharmaceuticals, Inc.
- Element Genomics
- Engage Therapeutics, Inc., Ra Pharmaceuticals, Inc.
- Schwarz Pharma
- UCB Biopharma
- Upstate Pharma, LLC
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.